Abstract
Co-administration of more than one drug targeting cardiovascular risk by impacting on serum lipoprotein metabolism is much less utilized than using combinations in the treatment of arterial hypertension or type 2 diabetes. Most commonly used lipid lowering drugs are statins, to which ezetimibe or bile acid sequestrants might be added when more profound decrease of LDL-cholesterol is required.
The results of clinical trials with some brand-new molecules used in the treatment of dyslipidemia hold a great promise - particularly the monoclonal antibodies against PCSK9 seem to offer unprecedented possibilities of impacting of lipid metabolism. However, even their place will be mainly within the combination lipid lowering regimens.
Statin and ezetimibe fixed-dose combos should be considered welcome tool in enhancing adherence, which is going to be even greater challenge to achieve in the future as more complicated and complex treatment regimens will be employed.